Compass Pathways to Attend Healthcare Conference

The psychedelic medicine company will present at the Needham Virtual Healthcare Conference.

Apr. 8, 2026 at 11:55am

Compass Pathways, a leading company in the field of psychedelic medicine, has announced that it will be attending the upcoming Needham Virtual Healthcare Conference on April 14, 2026. The conference provides a platform for healthcare companies to showcase their latest developments and engage with investors.

Why it matters

Compass Pathways' participation in this high-profile healthcare conference underscores the growing interest and investment in the emerging field of psychedelic-assisted therapies. As a pioneer in this space, the company's presence at the event will help raise awareness and showcase its advancements in the development of innovative mental health treatments.

The details

Compass Pathways, a biopharmaceutical company focused on the research and development of psilocybin therapy for treatment-resistant depression, will present at the Needham Virtual Healthcare Conference. The conference is a prestigious event that brings together leading healthcare companies, investors, and industry experts to discuss the latest trends and innovations in the sector.

  • The Needham Virtual Healthcare Conference will take place on April 14, 2026.

The players

Compass Pathways

A biopharmaceutical company focused on the research and development of psilocybin therapy for treatment-resistant depression.

Needham Virtual Healthcare Conference

A prestigious healthcare industry event that brings together leading companies, investors, and experts to discuss the latest trends and innovations in the sector.

Got photos? Submit your photos here. ›

What’s next

Investors and interested parties can tune in to Compass Pathways' presentation at the Needham Virtual Healthcare Conference on April 14, 2026 to learn more about the company's latest developments and future plans.

The takeaway

Compass Pathways' participation in the Needham Virtual Healthcare Conference underscores the growing momentum and investor interest in the field of psychedelic-assisted therapies, as the company continues to lead the way in the research and development of innovative mental health treatments.